Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: A randomized double-blind placebo-controlled trial

Archives of Medical Research

Volumn 45, Issue 5, 2014, Pages 388-393

  Rodríguez Moran, Martha ^a   Guerrero Romero, Fernando ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Glucose; Hypertension; Insulin resistance; Magnesium; Metabolically obese; Normal weight; Triglycerides

Indexed keywords

GLUCOSE; MAGNESIUM; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MALE; METABOLIC DISORDER; OBESITY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

GLUCOSE; HYPERTENSION; INSULIN RESISTANCE; MAGNESIUM; METABOLICALLY OBESE; NORMAL WEIGHT; TRIGLYCERIDES;

ADMINISTRATION, ORAL; ADULT; BODY WEIGHT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; MAGNESIUM CHLORIDE; MAGNESIUM DEFICIENCY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; TREATMENT OUTCOME;

EID: 84904701911     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.05.003     Document Type: Article

References (36)

1. Ruderman N.B., Schneider S.H., Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981, 34:1617-1621.
2. Conus F., Rabasa-Lhoret R., Péronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 2007, 32:4-12.
3. St-Onge M.P., Janssen I., Heymsfield S.B. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004, 27:2222-2228.
4. Ruderman N.B., Berchtold P., Schneider S. Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes 1982, 6(suppl 1):151-157.
5. Guerrero-Romero F., Rodriguez-Moran M. Serum magnesium in the metabolically-obese normal-weight and healthy-obese subjects. Eur J Intern Med 2013, 24:639-643.
6. Lopez Martinez J., Sanchez Castilla M., Garcia de Lorenzo y Mateos A., et al. Magnesium: metabolism and requirements. Nutr Hosp 1997, 12:4-14.
7. Paolisso G., Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997, 10:346-355.
8. Sontia B., Touyz R.M. Role of magnesium in hypertension. Arch Biochem Biophys 2007, 458:33-39.
9. Rodríguez-Morán M., Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003, 26:1147-1152.
10. Mooren F.C., Krüger K., Völker K., et al. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects-a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011, 13:281-284.
11. Guerrero-Romero F., Tamez-Perez H.E., González-González G., et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004, 30:253-258.
12. Chacko S.A., Sul J., Song Y., et al. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. Am J Clin Nutr 2011, 93:463-473.
13. Guerrero-Romero F., Rodríguez-Morán M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens 2009, 23:245-251.
14. Motoyama T., Sano H., Fukuzaky H. Oral magnesium supplementation in patients with essential hypertension. Hypertension 1989, 13:227-232.
15. Witteman J.C., Grobbee D.E., Derkx F.H., et al. Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am J Clin Nutr 1994, 60:129-135.
16. Ford E.S., Mokdad A.H. Dietary magnesium intake in a national sample of US adults. J Nutr 2003, 133:2879-2882.
17. Wildman R.P., Muntner P., Reynolds K., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
18. Geetha L., Deepa M., Anjana R.M., et al. Prevalence and clinical profile of metabolic obesity and phenotypic obesity in Asian Indians. J Diabetes Sci Technol 2011, 5:439-446.
19. Lee K. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. Asia Pac J Clin Nutr 2009, 18:280-284.
20. Mejía-Rodríguez F., Shamah-Levy T., Villalpando S., et al. Iron, zinc, copper and magnesium deficiencies in Mexican adults from the National Health and Nutrition Survey 2006. Salud Publica Mex 2013, 55:275-284.
21. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
22. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013, 31:1281-1287. List of authors Task Force members.
23. Mejía-Aranguré J.M., Fajardo-Gutierrez A., Gómez-Delgado A., et al. El tamaño de la muestra. Un enfoque práctico en la investigación clínica pediátrica. Bol Med Hosp Infant Mex 1995, 52:381-391.
24. Rumawas M.E., McKeown N.M., Rogers G., et al. Magnesium intake is related to improved insulin homeostasis in the Framingham offspring cohort. J Am Coll Nutr 2006, 25:486-492.
25. Hopping B.N., Erber E., Grandinetti A., et al. Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J Nutr 2010, 140:68-74.
26. Lopez-Ridaura R., Willett W.C., Rimm E.B., et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004, 27:134-140.
27. Kirii K., Iso H., Date C., et al. Magnesium intake and risk of self-reported type 2 diabetes among Japanese. J Am Coll Nutr 2010, 29:99-106. JACC Study Group.
28. Song Y., Manson J.E., Buring J.E., et al. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004, 27:59-65.
29. Kim D.J., Xun P., Liu K., et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010, 33:2604-2610.
30. Guerrero-Romero F., Rascón-Pacheco R.A., Rodríguez-Morán M., et al. Hypomagnesemia and risk for metabolic glucose disorders: a 10-y follow-up study. Eur J Clin Invest 2008, 38:389-396.
31. Guerrero-Romero F., Rodríguez-Morán M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabet Metab Res Rev 2008, 22:471-476.
32. Barbagallo M., Dominguez L.J., Resnick L.M. Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am J Ther 2007, 14:375-385.
33. Barbagallo M., Dominguez L.J. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007, 458:40-47.
34. Rosanoff A., Plesset M.R. Oral magnesium supplements decrease high blood pressure (SBP >155mmHg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analysis. Magnes Res 2013, 26:93-99.
35. Rodríguez-Moran M., Guerrero-Romero F. Hypomagnesemia and prehypertension in otherwise healthy individuals. Eur J Intern Med 2014, 25:128-131.
36. Guerrero-Romero F., Rodríguez-Morán M., Pérez-Fuentes R., et al. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord 2008, 6:15-23.